Medicinal preparation for treatment of diabetes and method of its preparation


FIELD: medicine.

SUBSTANCE: medicinal preparation for diabetes treatment contains active pharmaceutical ingredients, obtained from root of rehmania (Radix Rehmanniae), root of astragalus (Radix Astragali), rhizomes of yam (Rhizoma Dioscoreae), root of kudzu hemp (Radix Puerariae Lobatae), root of snake gourd (Radix Trichosanthis), baculums with stigmas of corn (Stylus Zeae Maydis), fruits of schizandra (Fructus Schisandrae Sphenantherae) and Glibenclamidum (Glibenclamide), taken in a certain parity. Way of preparation of a medicinal preparation in the form of drop-pills. A way of preparation of a medicinal preparation in the form of pills. A way of preparation of a medicinal preparation in the form of capsules. A way of preparation of a medicinal preparation in the form of tablets. A way of preparation of a medicinal preparation in the form of granules. A way of preparation of a medicinal preparation in the form of soft capsules. A way of preparation of a medicinal preparation in the form of a powder.

EFFECT: efficiency for diabetes treatment.

14 cl, 3 tbl, 18 ex

 

The technical FIELD

This invention relates to medicine, in particular to the formula, combining Chinese and Western medicine for treatment of diabetes.

PRIOR art

In traditional Chinese medicine diabetes mellitus (diabetes) is also called the disease of Xiao Ke (Xiao Ke). It is an endocrine metabolic disease characterized by hyperglycemia as a result of absolute or relative lack of insulin. Main clinical symptoms: polydipsia, polyphagia, polyuria, and cachexia. Diabetes mortality and the incidence of diseases such as: heart disease, stroke, blindness, 2-5 times higher than that of adiabatic, ulcers of the lower extremities and the percentage of amputations 20 times higher than that of adiabatic.

In developed countries, diabetes is on the third place among the noncommunicable disease after cardiovascular diseases and neoplasm/cancer and became a global problem that threatens human health.

Studies have shown that the incidence of diabetes people in the world amounted to 120 million in 1994, 135 million in 1997, $ 175 million in 2000. According to the calculations in 2010, the number of cases will reach 239 million. In developing countries, the incidence has increased by 200%. China, India and some developing countries in Africa are the main regions affected is evenote. Hospital and market - both require highly effective means for the treatment of diabetes.

Currently diabetes in the majority of cases treated by chemical synthesis, which brings satisfactory short-term effect, but rather weak effect in long-term treatment and has no side effects and complications.

Chinese patent application No. CN 1562188A, published January 12, 2005, describes a drug for the treatment of diseases "Xiao Ke" (diabetes), consisting of 4000 grams of Pueraria root (Radix Puerariae), 240 grams of the root of Rehmannii (Radix Rehmanniae), 80 grams of Astragalus root (Radix Astragali), 400 grams of root Trichosanthes (Radix Trichosanthis), 400 grams of columns with stigmas of maize (Stylus Zeae Maydis), 80 grams of the fruit of schisandra chinensis (Fructus Schisandrae Sphenantherae), 40 grams rhizomes of Dioskoreya (Rhizoma Dioscoreae) and 0.3 grams of Glibenclamide (Glibenclamide). In this formula the root of Pueraria is the main drug is 4000 parts by weight, while the other drugs are only 1240 parts by weight. Dosage of Pueraria root is much higher doses of the other ingredients in the formula and the standard clinical dosing in Chinese Pharmacopoeia, which undermines the effects of other drugs in the formula. The composition of this formula is obviously unreasonable. In addition, according to the conventional methods of manufacturing, with a larger number of Pueraria root extraction to what I obtained liquid extract is great so the dosage of this drug is high and difficult to use.

The INVENTION

The aim of the invention is the creation of a new drug, taking into account various traditional Chinese medicine to increase its effectiveness.

To achieve the above objectives, the invention provides a pharmaceutical preparation for the treatment of diabetes, active pharmaceutical ingredients which are obtained from the following source materials:

600-1200 parts by weight of root Rehmannii (Radix Rehmanniae), 200-400 parts by weight of Astragalus root (Radix Astragali), 100-200 parts by weight of rhizomes of Dioskoreya (Rhizoma Dioscoreae), 1000-2000 parts by weight of root Pueraria lobed (Radix Puerariae Lobatae), 1000-2000 parts by weight of root Trichosanthes (Radix Trichosanthis), 1000-2000 parts by weight of columns with stigmas of maize (Stylus Zeae Maydis), 200-400 parts by weight of the fruit of Chinese Magnolia vine (Fructus Schisandrae Sphenantherae) and 0.2-1.5 parts by weight of Glyburide (Glibenclamide).

Preferably, the active pharmaceutical ingredients of a medicinal product was obtained from the following source materials:

600-900 parts by weight of root Rehmannii, 200-300 parts by weight of the root of Astragalus, 100-150 parts by weight of rhizomes of Dioskoreya, 1000-1500 parts by weight of root Pueraria lobed, 1000-1500 parts by weight of root Trichosanthes, 1000-1500 parts by weight of columns with stigmas of maize, 200-300 parts by weight of fruits Chinese lemon the CA and 0.2-1.0 parts by weight of Glibenclamide.

Even more preferably, the active pharmaceutical ingredients of a medicinal product was obtained from the following source materials:

636 parts by weight of root Rehmannii, 212 parts by weight of the root of Astragalus, 106 parts by weight of rhizomes of Dioskoreya, 1060 parts by weight of root Pueraria lobed, 1060 parts by weight of root Trichosanthes, 1060 parts by weight of columns with stigmas of maize, 212 parts by weight of the fruit of Chinese Magnolia vine, and 1 part of weight of Glibenclamide.

The drug, according to the present invention is based on the formulas Yu Quan San ("Yu quan San"), Jiao Ke Fang ("Xiao Ke Fang"), owned by well-known doctor, Tianshi (Ye Tianshi) of the Qing dynasty (Qing), which has been modified to support kidney support forces (tone) and increased production of body fluid. In the formula the root of Rehmannii is used to supply the kidneys, Astragalus root to support forces (toning), increased production of body fluid and quench your thirst with these two drugs play a major role in the formula; the rhizome Dioscorea serves to improve lung and spleen, support lung and kidney, and together with the root of Rehmannii to power the Yin and treatment of the kidneys; the root of Pueraria serves to increase the Yang energy and increase production of body fluid, with the assistance of Astragalus root is used to improve the functioning of the spleen, DOS is where it is refuelled essences to light, these two drugs play an important role in the formula; the root of Trichosanthes clears pathogenic stomach, to power the stomach, moistening the lungs, reducing the excitation and increased thirst/polydipsia to an average level. Columns with stigmas of maize are used for diuresis to relieve swelling, to coordinate functions of the kidneys, these two drugs play a supporting role in the formula; the fruit of Chinese Magnolia vine are used to support the lungs at the top, to strengthen the kidneys and increase the production of body fluid from the bottom, calm the psyche inside and reduce sweating outside, play the role of the conductor in the formula. The complex formula is used to supply the kidney, boost energy and increase production of body fluid. Glibenclamide (Western medicine) is used to relieve symptoms of illness Xiao Ke and reduce blood sugar levels.

All active pharmaceutical ingredients in the drug, in accordance with the present invention, based on theory of traditional Chinese medicine and the experience of practical application. The formula consists of well-chosen substances in the correct proportions, and the effect of it much better than from the drug, described in the Chinese patent application No. CN 1562188A, and Glibenclamide. Thus, the purpose of this invention is to provide patients with diabetes are more safe and effective drug reached.

In accordance with the requirements of the pharmaceutical formula can be prepared in various forms for clinical use, including in the form of drops-pills, pills, tablets, capsules, dispersible granules, capsules, soft shell and powder.

The process of making the above forms

I Cook drops pills

The root of Pueraria lobed, the root of Rehmannii, columns with stigmas of maize, root Trichosanthes, Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea brewed with water, then filtered, and the filtrate concentrated (evaporated) to a moderate amount (modest) and placed on the cooling. Ethanol (Ethanol) is added to the filtrate to make a solution containing 60% ethanol, and this solution is settled for 24 hours and then filtered, the filtrate evaporated (concentrated)to get rid of the smell of ethanol. To the concentrate is added to two parts of water, and all this baltyboys until dissolved. Then, the solution is placed in the prepared macroporous resin and the resin is eluted with water to bleaching eluent. Next, the resin is eluted with 70% ethanol, collected eluent to until will not discolor, and is concentrated in the extract. A moderate amount of polyethylene Glycol 6000 (Polyethylene Glycol 6000 (PEG-6000) and stearic acid (stearic-id) capacity is placed in the ü and heated to 100-110°, until the mixture is completely dissolved, then added Glibenclamide and above extract. After uniform dissolution are drop-pills/tablets by using liquid paraffin as a cooling agent, then drops pills are extracted and dried from a paraffin base.

II Preparation of pills

Method 1: root Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered and concentrated (evaporated) the filtrate is modest thus, to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, fine powder proshlifovyvayutsya in the water (water), then dried, after that added Glibenclamide, pills retrieved using black iron oxide (ferric black oxide), talcum powder (talcum powder) and a binder agent as a covering substance, then polished floor and then dried.

Method 2: root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered and concentrated (viparis who are in moderate extent so to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder, and the powder is well mixed with the liquid concentrate is then dried and pounded into a fine powder; pills are made using machines for the manufacture of pills and then dried, is added to Glyburide, pills retrieved using black iron oxide, talc powder and a bonding agent as a covering substance, then polished floor and then dried.

Method 3: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder, and the powder is well mixed with the liquid concentrate is then dried and pounded into a fine powder; granules are made in a single-stage granulator, is added to Glyburide and pills are obtained by pressing.

Method 4: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in temperate scale so the m way to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded into a fine powder; fine powder is converted into pellets in a single-stage granulator with liquid concentrate is added to Glyburide and pills are manufactured by pressing.

III Preparation of capsules

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder, and the powder is well mixed with the liquid concentrate is then dried and pounded into a fine powder, then added Glibenclamide and a moderate amount of dextrin (dextrin) and well mixed with the above-mentioned fine powder for the preparation of granules, which are then placed in capsules.

IV Preparation tablets

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizomes is Dioscorea pounded in a large powder, and the powder is well mixed with the liquid concentrate is then dried and pounded into a fine powder, then added Glibenclamide and a moderate amount of dextrin and well mixed with the above-mentioned fine powder for the preparation of granules, which are then dried and mixed with 0.5% magnesium stearate (magnesium stearate) for pressing into tablets.

V Preparation of soluble granules

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder, which is then well mixed with the liquid concentrate is dried and pounded into a fine powder; add in fine powder Glibenclamide and a moderate amount of dextrin, well mixed, to obtain granules.

VI Preparation of soft capsules/capsules in a soft shell

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; the bark is ü Astragalus, the fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder, and the powder is well mixed with the liquid concentrate is then dried and pounded into a fine powder; then add the Glibenclamide and well mixed with a fine powder, then added the same number of polyethylene Glycol-400 (Poly ethylene Glycol-400) and a small amount of glycerin, well mixed and pressed into soft capsules.

VII Cooking powder

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder, and the powder is well mixed with the liquid concentrate is then dried and pounded into a fine powder; then add the Glibenclamide and well mixed with a fine powder to obtain the final powder.

Drug related to this invention, has a robust manufacturing methods and control in proportions. Technical study is as follows.

1. Materials and methods

1.1. Materials

"The drug (medicine) Xiao Ke" here esgotos is carried out according to the method 4 Chinese patent application No. CN 1562188A.

"The drug (medicine) the present invention" here is referring to the method 1 of the present invention.

1.2. Methods

1.2.1

1.2.2 the Rest of the ingredients are applications Pharmacopoeia of China (2000 items).

2. Data

IngredientThe drug Xiao KeThe drug of this invention
The resulting proportion of extract25 ~ 30%15 ~ 18%
PillsExternal signsflatround, flat, uniform color
The dissolution/absorption107 min<80 min
CapsulesThe nature of the contentEasily contact in the columnHomogeneous granules
The dissolution/absorption30 min<20 min
TabletsIn EMA decomposition/digestion 64 min<50 min

Conclusion:

The above experiments show that the composition of the drug (medication) according to the present invention is more rational, technologically advanced, sustainable, smaller dosage and quality of the final product is stable and controlled. Compared with the existing technology of the product presented in this invention has high stability; the final product has good assalaamu and homogeneity.

The effect of the drug in the present invention, is illustrated through the following pharmacodynamic experiments on animals.

1. Materials and methods

1.1 Materials

1.1.1 Medicines and reagents

"The drug Xiao Ke" (powder) in this case is produced by the method 4 from Chinese patent application No. CN 1562188A, while the drug of the present invention (in this case, the powder is produced according to the method 1 of the present invention. Before the experiment, the powders were diluted with water to a certain concentration.

Glibenclamide: products Medical Institute Tianjin (Tianjin Drugs Institute), China.

Streptozotocin (Streptozotcin): products of Sigma (Sigma), USA.

Standard glucose solution: products of the Shanghai Institute of biological products (Shanghai Institute of Biological Products).

The glucose oxidases (Glucoseoxidase): Guangdong Local Clinical Trial Center (Guangdong Provincial Clinical Test Center).

Standard solution of cholesterol (cholesterol): products of Beijing Chemical industrial factory (Beijing Chemical Industry Factory).

Test packing triacylglycerol (Triacylglycerol Test Box) (import): Packed in Shanghai Chanting" Medical Research company (Shanghai Changzheng Medical Science Co.).

The drug high fat emulsion: cholesterol 5 grams (imported from Holland), detoxination Holt (deoxysodium cholate) 0.3 gram (products "Serva" (SERVA) USA), pork fat 20 grams (store-bought), half dose of ether polyoxyethylene fatty acids (polysorbate) 80 (import from Japan) and half-dose 1, 2 propylene glycol (propylene glycol) (production of the First Reagent Factory, Shanghai (First Reagent Factory of Shanghai) to prepare 50 ml of the emulsion.

1.1.2 Basic tools: input type fully automatic biochemical apparatus for analysis (production company Kangning (Kangning Co.) USA).

1.1.3 Animals: NIH mice and SD rats (supplied Grindingly Farm Animals (Guangdong Experimental Animal Farm) for experiments).

1.2 Methods

1.2.1 Impact on blood sugar levels normal mouse

40 healthy mice (half male, half female) weighing 23-25 g were randomly divided into 4 groups (10 mice in each group). Normal control group is lnyh experimental animals were injected with equal amount of normal saline intragastrically; the positive control group, experimental animals were given Glibenclamide (2 mg/kg) intragastrically; control group experimental animals "Xiao Ke of the drug (CRU)" gave the drug Xiao Ke intragastrically, which is tantamount 34.94 g/kg crude drugs and contains 2 mg of Glibenclamide; the group representing "the drug of the present invention, was given the drug, according to the present invention, intragastric, which is equivalent to 8.64 g/kg crude drugs and contains 2 mg of Glibenclamide. The mouse ate the usual way for 3 days and then fasted for 12 hours, and took blood from the eyeball. The sugar level in the blood was determined by the glucose oxidase test (glucoseoxidase test) and were taken as the base level of sugar in the blood. Then the mice were individually given drugs intragastrically through 3 and 7 hours after the medication is individually determined by the level of sugar in the blood. The value of the base level of sugar in the blood minus the blood sugar levels after taking the medication is a characteristic of reducing blood sugar level.

1.2.2 Impact on blood sugar levels of diabetic rats initiated Streptozotocin.

Healthy rats (half male, half female) weighing 150-180 g were fed in the usual manner for 5 days and then fasted for 12 hours, and was quickly introduced Streptozotocin (50 mg ml/kg, prepared with the hydrogen index (pH) 4.5 buffer solution of citric acid) into a vein in the tail of rats to install the models (standards) animals.

The usual group was administered an equal amount of buffer solution. After 2 weeks, we determined the level of sugar in the blood, and rats whose blood sugar level is exceeded 16.8 mmol/l and glucose in the urine was constantly +++, was chosen as rats, satisfying the requirements (UT). Rats that meets the requirements (UT), were randomly divided into 4 groups. Normal control group experimental animals was also determined. The drugs were given individually intragastrically once a day for 4 weeks. The normal and the reference group received an equal amount of normal saline intragastrically. The positive control group, experimental animals were given Glibenclamide (1 mg/kg) intragastrically. Control group experimental animals "Xiao Ke drug (SSI)" gave medicine Xiao Ke intragastrically, which is tantamount 17.47 g/kg crude drugs and contains 1 mg of Glibenclamide; the group representing the product of the present invention, gave the product presented in this invention, intragastric, which is equivalent to 4.32 g/kg crude drugs and contains 1 mg of Glibenclamide. After the suspension of the medication, the blood sugar level was measured n the next day using a glucose oxidase test (glycoseoxidase test) to compare the differences between different groups.

1.2.3 Impact on cholesterol, triacylglycerols, liver function, kidney function and blood rheology in rats diabetics complicated by hyperlipidemia (hyperlipemia).

Method for the determination of rat models of diabetes caused by Streptozotocin, the same as in experiment 1.2.2. 40 selected rats randomly divided into 4 groups, normal control group experimental animals was also determined. The drugs were given individually intragastrically once a day for 4 weeks. The normal and the reference group received an equal amount of normal saline intragastrically. The positive control group, experimental animals were given Glibenclamide (1 mg/kg) intragastrically. Control group experimental animals "Xiao Ke of the drug (CRU)" gave the drug Xiao Ke intragastrically, which is equivalent 17.47 g/kg crude drugs and contains 1 mg of Glibenclamide; the group representing "the drug of the present invention, gave the product presented in this invention intragastrically, which is equivalent to 4.32 g/kg crude drugs and contains 1 mg of Glibenclamide. The drugs were given individually in the morning and 5 ml/kg high fat emulsion was given individually day continuously for 3 weeks. After suspension of treatment, and 12-hour fast has introduced the b light anesthesia with ether and took blood samples from the heart, to determine the cholesterol level (using sulfate colored dough (sulfate color test)and the level of triacylglycerol (using the method of semologie (zymologic method-GPO).

1.3 Statistical data displayed in the form ofdifferences between groups were analyzed using t-test/check on the student test (t-test).

2. Results

2.1 Impact on blood sugar levels normal mice (see table 1).

Table 1
Impact on blood sugar levels normal mouse (±s, n=10)
GroupDosageBasic sugar levelReducing sugar levels after treatment(mmol/l)
g)(g/k in the blood (mmol/l)3 h after the treatment7 hours after treatment
Control-4.70±0.901.37±0.930.99±1.17
Glibenclamide2 is 10-3 5.26±1.592.07±0.46*3.23±1.57**
Xiao Ke
medication34.944.83±1.232.12±0.63*3.17±1.67**
The medication of
present
inventions8.645.14±1.522.25±0.42*3.43±1.55**

Note: compared with control group:*P<0.05;**P<0.01 (copy)

2.2 Impact on blood sugar levels of diabetic rats initiated Streptozotocin (see table 2).

Table 2

Impact on blood sugar levels of diabetic rats initiated Streptozotocin (±s, n=10)

Dosage (g/kg)Sugar levels
in blood (mmol/l)
Before the treatmentReduction after treatment
Normal-5.56±0.950.25±0.11
Control (model)-At 24.23±3.94-1.52±4.69
Glibenclamide1×10-325.64±3.472.90±3.02*
Xiao Ke
medication17.4725.19±2.983.05±1.90*
The drug of the present invention4.32At 24.69±3.733.66±2.57**

2.3 Impact on cholesterol, triacylglycerol, liver function, kidney function and blood rheology in rats diabetics complicated by hyperlipidemia (see table 3).

Table 3
Effects on cholesterol, triacylglycerol, liver function, kidney function and blood rheology in rats diabetics complicated by hyperlipidemia (±s, n=10)
GroupDosage (g/kg)Total serum cholesterol (mmol/l) (serum total cholesterol mmol/L)Serum triacylglycerol (MMon/n) (serum triacylglycerol mmol/L)
Normal-0.60±0.281.48±0.49
Control (model)-1.59±0.512.96±1.45
Glibenclamide1×10-31.44±0.432.52±1.12
Xiao Ke medication17.471.25±0.331.95±0.71
The medication of4.320.96±0.21**1.58±0.71*
present
inventions

Note: comparison with Glibenclamide group and group drug Xiao Ke": *P<0.05; **P<0.01.

Conclusion:1.

1. The experiments showed that Glibenclamide group, a group of "drug Xiao Ke" and the "Drug of the present invention" - all give the effect of reducing the level of blood sugar in the normal mice and diabetic rats initiated Streptozotocin (DRIS), compared with the control group, P<0.05 or P<0.01. But there is no significant difference in effect between the three groups. The drug is presented in this invention, gives indisputable effect of impeding growth in total serum cholesterol and triacylglycerol in rats diabetics complicated by hyperlipidemia, compared with the control group, the Glibenclamide group, a group of drug Xiao Ke", P<0.05 or P<0.01. Glyburide and drug Xiao Ke does not have this effect. This suggests that the effect of the drug in the present invention, is superior to the effect of the drug Xiao Ke and Glibenclamide.

2. Invented the drug consists of carefully selected materials with the correct proportions based on theories of traditional Chinese medicine and practical experience, the effect of it is clearly superior to the drug Xiao Ke and Glibenclamide. Dosirak is significantly less than drug Xiao Ke, which makes it more comfortable when worn for themselves. As a result, the drug is presented in this invention is safe and effective in the treatment of diabetes.

DETAILED description of the INVENTION

Method 1: Making pills

The number of active pharmaceutical raw materials and Glibenclamide is determined in the following proportions: the root of Rehmannii: 636 parts by weight; Astragalus root: 212 parts by weight; the rhizome Dioscorea: 106 parts by weight; the root of Pueraria lobed: 1060 parts by weight; root Trichosanthes: 1060 parts by weight; columns with stigmas of maize: 1060 parts by weight; the fruit of Chinese Magnolia vine: 212 parts by weight and Glibenclamide: 1 piece weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated to a moderate quantity so as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder and well mixed; fine powder proshlifovyvayutsya water (in the water), then dried, then added to the iron oxide, talc powder, a moderate amount is about bonding agent and Glibenclamide, pills are obtained after polishing coating pills.

The implementation method 2: Making pills

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions: the root of Rehmannii: 600 parts by weight; Astragalus root: 200 parts by weight; the rhizome Dioscorea: 100 parts by weight; the root of Pueraria lobed: 1000 parts by weight; root Trichosanthes: 1000 parts by weight; columns with stigmas of maize: 1000 parts by weight; the fruit of Chinese Magnolia vine: 200 pieces weight and Glibenclamide: 1.5 frequent. weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate concentrated (evaporated) modest thus, to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate, then pounded into a fine powder and well mixed; fine powder otshlifovanye in the water (water), then dried, then added to the iron oxide, talc powder and a moderate amount of the binder agent and Glibenclamide, pills are obtained by polishing the coating of pills.

The implementation method 3: Manufacturing capsules

The number of pharmaceutical source mater what Alov and Glibenclamide is determined in the following proportions: the root of Rehmannii: 636 parts by weight; Astragalus root: 212 parts by weight; the rhizome Dioscorea: 106 parts by weight; the root of Pueraria lobed: 1060 parts by weight; root Trichosanthes: 1060 parts by weight; columns with stigmas of maize: 1060 parts by weight; the fruit of Chinese Magnolia vine: 212 parts by weight and Glibenclamide: 1 piece weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, add Glibenclamide and a moderate amount of dextrin and well stirred to prepare granules, which are then filled capsules.

The implementation method 4: Manufacturing capsules

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions: the root of Rehmannii: 1200 parts by weight; Astragalus root: 400 parts by weight; the rhizome Dioscorea: 200 parts by weight; the root of Pueraria lobed: 2000 piece weight; root Trichosanthes: 2000 parts by weight; the columns with stigmas and corn: 2000 parts by weight; the fruit of Chinese Magnolia vine: 400 parts by weight and Glibenclamide: 0.2 part by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, then add the Glibenclamide and a moderate amount of dextrin and well mixed to prepare granules, which are then filled capsules.

The implementation method 5: Making tablets

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 636 parts by weight; Astragalus root: 212 parts by weight; the rhizome Dioscorea: 106 parts by weight; the root of Pueraria lobed: 1060 parts by weight; root Trichosanthes: 1060 parts by weight; columns with stigmas of maize: 1060 parts by weight; the fruit of Chinese Magnolia vine: 212 parts by weight and Glibenclamide: 1 piece weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate concentrate eroitca modest thus, to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, fine powder is added to Glyburide and moderate amount of dextrin and well mixed to prepare granules, the granules are dried and mixed with 0.5% magnesium stearate (magnesium stearate), and then pressed into tablets.

The implementation method 6: Making tablets

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 1200 parts by weight; Astragalus root: 400 parts by weight; the rhizome Dioscorea: 200 parts by weight; the root of Pueraria lobed: 2000 piece weight; root Trichosanthes: 2000 piece weight; columns with stigmas of maize: 2000 parts by weight; the fruit of Chinese Magnolia vine: 400 parts by weight and Glibenclamide: 1.5 parts by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid to which ncentration, then dried and pounded into a fine powder, fine powder is added to Glyburide and moderate amount of dextrin and well mixed to prepare granules, the granules are dried and mixed with 0.5% magnesium stearate, and then pressed into tablets.

The method of implementation 7: Production of soluble granules

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 600 parts by weight; Astragalus root: 200 parts by weight; the rhizome Dioscorea: 100 parts by weight; the root of Pueraria lobed: 1000 parts by weight; root Trichosanthes: 1000 parts by weight; columns with stigmas of maize: 1000 parts by weight; the fruit of Chinese Magnolia vine: 200 pieces weight and Glibenclamide: 0.2 part by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, fine powder is added to Glyburide and moderate amount of dextrin and well mixed prepared for what I soluble granules.

Method of implementation 8: Manufacture of soft capsules/capsules in a soft shell

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 900 parts by weight; Astragalus root: 300 parts by weight; the rhizome Dioscorea: 150 weight parts; the root of Pueraria lobed: 1500 parts by weight; root Trichosanthes: 1500 parts by weight; columns with stigmas of maize: 1500 parts by weight; the fruit of Chinese Magnolia vine: 300 parts by weight and Glibenclamide: 0.2 parts by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, fine powder is added to Glyburide and well mixed, then added the same number of polyethylene Glycol 400 and a small amount of glycerin, well mixed and pressed into capsules with a soft shell.

Method of implementation 9: Manufacture of powder

The number of pharmaceutical raw materials and Glibenclamide is defined in the following the proportions:

the root of Rehmannii: 900 parts by weight; Astragalus root: 300 parts by weight; the rhizome Dioscorea: 150 weight parts; the root of Pueraria lobed: 1500 parts by weight; root Trichosanthes: 1500 parts by weight; columns with stigmas of maize:1500 parts by weight; the fruit of Chinese Magnolia vine: 300 parts by weight and Glibenclamide: 1 parts by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, then add the Glibenclamide and well mixed, it received the necessary powder.

Method of implementation 10: Making pills

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 600 parts by weight; Astragalus root: 200 parts by weight; the rhizome Dioscorea: 100 parts by weight; the root of Pueraria lobed: 1000 parts by weight; root Trichosanthes: 1000 parts by weight; columns with stigmas of maize:1000 parts by weight; the fruit of Chinese Magnolia vine: 200 pieces weight and Glibenclamide: 1 piece weight.

The bark is ü Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder; fine powder proshlifovyvayutsya in the water (water), then dried, then added to the iron oxide, talc powder and a moderate amount of the binder agent and Glibenclamide, pills are obtained after polishing coating pills and drying.

Method of implementation 11: Manufacture pills

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 900 parts by weight; Astragalus root: 200 parts by weight; the rhizome Dioscorea: 130 parts by weight; the root of Pueraria lobed: 1100 parts by weight; root Trichosanthes: 1200 parts by weight; columns with stigmas of maize:1300 parts by weight; the fruit of Chinese Magnolia vine: 250 parts by weight and Glibenclamide: 0.5 part by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate concentrate eroitca modest thus, to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder; fine powder proshlifovyvayutsya in the water (water), then dried, then added to the iron oxide, talc powder and a moderate amount of the binder agent and Glibenclamide, pills are obtained after polishing coating pills and drying.

Method of implementation 12: Manufacture pills

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 750 parts by weight; Astragalus root: 250 parts by weight; the rhizome Dioscorea: 130 parts by weight; the root of Pueraria lobed: 1300 parts by weight; root Trichosanthes: 1300 parts by weight; columns with stigmas of maize:1300 parts by weight; the fruit of Chinese Magnolia vine: 250 parts by weight and Glibenclamide: 0.5 part by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and good paramashiva is carried out with liquid concentrate, then dried and pounded into a fine powder; fine powder proshlifovyvayutsya in the water (water), then dried, then added to the iron oxide, talc powder and a moderate amount of the binder agent and Glibenclamide, pills are obtained after polishing coating pills and drying.

Method of implementation 13: Manufacture tablets

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii 1000 parts by weight, Astragalus root 220 parts by weight, rhizome Dioscorea 110 parts by weight, the root of Pueraria lobed 1000 parts by weight, root Trichosanthes 1700 parts by weight, columns with stigmas of maize 1500 parts by weight, the fruit of Chinese Magnolia vine 205 parts by weight and Glibenclamide 0.4 part by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, fine powder is added to Glyburide and moderate amount of dextrin and well mixed on the I preparation of granules, which are then dried and well mixed with 0.5% magnesium stearate (magnesium stearate and pressed into tablets.

Method of implementation 14: Production of soluble granules

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 650 parts by weight; Astragalus root: 205 parts by weight; the rhizome Dioscorea: 120 weight parts; the root of Pueraria lobed: 1700 parts by weight; root Trichosanthes: 1500 parts by weight; columns with stigmas of maize:1100 parts by weight; the fruit of Chinese Magnolia vine: 220 parts by weight and Glibenclamide: 0.8 parts by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, fine powder is added to Glyburide and moderate amount of dextrin and well mixed to prepare soluble granules.

Method of implementation 15: Manufacture of soft capsules (soft shell)

The number of pharmaceutical raw materials and Glienke the IDA is determined in the following proportions:

the root of Rehmannii: 950 parts by weight; Astragalus root: 350 parts by weight; the rhizome Dioscorea: 180 weight parts; the root of Pueraria lobed: 1500 parts by weight; root Trichosanthes: 1100 parts by weight; columns with stigmas of maize:1200 parts by weight; the fruit of Chinese Magnolia vine: 280 parts by weight and Glibenclamide: 1.2 parts by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate is concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, fine powder is added to Glyburide and well mixed, then added the same number of polyethylene Glycol 400 and a small amount of glycerin, well mixed and pressed into capsules with a soft shell.

Method of implementation 16: Manufacture of powder

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 800 parts by weight; Astragalus root: 210 parts by weight, rhizome Dioscorea: 100 parts by weight; the root of Pueraria lobed: 1200 parts by weight; root Trichosanthes: 1000 h the values of the weight; columns with stigmas of maize:1700 parts by weight; the fruit of Chinese Magnolia vine: 330 parts by weight and Glibenclamide: 0.9 part by weight.

The root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize steep water for 5 hours, then filtered, and the filtrate concentrated (evaporated) modest thus, to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pounded in a large powder and well mixed with the liquid concentrate is then dried and pounded into a fine powder, fine powder is added to Glyburide and well mixed, it received the necessary powder.

Method of implementation 17: Production drops pills

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 636 parts by weight; Astragalus root: 212 parts by weight; the rhizome Dioscorea: 106 parts by weight; the root of Pueraria lobed: 1060 parts by weight; root Trichosanthes: 1060 parts by weight; columns with stigmas of maize:1060 parts by weight; the fruit of Chinese Magnolia vine: 212 parts by weight and Glibenclamide: 1 piece weight.

The root of Pueraria lobed, the root of Rehmannii, columns with stigmas of maize, root Trichosanthes, Astragalus root, fruit of Chinese Magnolia vine and cornelisjonkers brewed with water, then filtered, and the filtrate concentrated in the moderate scale and placed on the cooling. Ethanol is added so that the solution contained 60% ethanol, and this solution is settled for 24 hours, then filtered, the filtrate is concentrated to get rid of the smell of ethanol; in the concentrate is added to two parts of water and baltyboys until dissolved. Next, the resulting solution is placed in the prepared macroporous resin, and the resin is eluted with water to bleaching eluent. The resin is eluted with 70% ethanol eluent going to discoloration eluent and concentrated in the extract. A moderate amount of polyethylene Glycol 6000 (PEG-6000) and stearic acid are placed in a beaker and heated to 100-110°C. until the mixture is completely dissolved, after which is added to Glyburide and above extract. After uniform dissolution of formed drops pills with liquid paraffin is used as the cooler. Drops pills work after they are extracted and dried on wax.

Method of implementation 18: Production drops pills

The number of pharmaceutical raw materials and Glibenclamide is determined in the following proportions:

the root of Rehmannii: 750 parts by weight; Astragalus root: 250 parts by weight; the rhizome Dioscorea: 130 parts by weight; the root of Pueraria lobed: 100 parts by weight; root Trichosanthes: 1300 parts by weight; columns with stigmas of maize:1300 parts by weight; the fruit of Chinese Magnolia vine: 250 parts by weight and Glibenclamide: 0.5 part by weight.

The root of Pueraria lobed, the root of Rehmannii, columns with stigmas of maize, root Trichosanthes, Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea brewed with water, then filtered, and the filtrate is concentrated to regulate the number and placed on the cooling. Ethanol is added so that the solution contained 60% ethanol, and this solution is settled for 24 hours, then filtered, the filtrate is concentrated to get rid of the smell of ethanol. To the concentrate is added to two parts of water, and all this baltyboys until dissolved. Next, the resulting solution is placed in the prepared macroporous resin, and the resin is eluted with water to bleaching eluent. The resin is eluted with 70% ethanol. Eluent is going to discoloration and concentrated in the extract. A moderate amount of polyethylene Glycol 6000 (PEG-6000) and stearic acid are placed in a beaker and heated to 100-110°C. until the mixture is completely dissolved, and then added to Glyburide and above extract and uniformly dissolved. Then after uniform dissolution using liquid paraffin used as a cooler, get drops pills. To the PLI-pills obtained after as they are extracted and dried on wax.

1. Drug for the treatment of diabetes mellitus, characterized in that the active pharmaceutical ingredients of a medicinal product derived from the following pharmaceutical raw materials:
600-1200 parts by weight of root Rehmannii (Radix Rehmanniae), 200-400 parts by weight of Astragalus root (Radix Astragali), 100-200 parts by weight of the rhizomes Dioscorea (Rhizoma Dioscoreae), 1000-2000 parts by weight of root Pueraria lobed (Radix Puerariae Lobatae), 1000-2000 parts by weight of root Trichosanthes (Radix Trichosanthis), 1000-2000 parts by weight of columns with stigmas of maize (Stylus Zeae Maydis), 200-400 parts by weight of the fruit of Chinese Magnolia vine (Fmctus Schisandrae Sphenantherae) and 0.2 to 1.5 parts by weight of Glyburide (Glibenclamide).

2. The drug according to claim 1, characterized in that the active pharmaceutical ingredients of a medicinal product derived from the following pharmaceutical raw materials:
600-900 parts by weight of root Rehmannii, 200-300 parts by weight of the root of Astragalus, 100-150 parts by weight of the rhizomes Dioscorea, 1000-1500 parts by weight of root Pueraria lobed, 1000-1500 parts by weight of root Trichosanthes, 1000-1500 parts by weight of columns with stigmas of maize, 200-300 parts by weight of the fruit of Chinese Magnolia vine and 0.2 to 1.0 parts by weight of Glibenclamide.

3. The drug according to claim 2, characterized in that the active pharmaceutical ingredients of a medicinal product derived from the trace of the General pharmaceutical raw materials:
636 parts by weight of root Rehmannii, 212 parts by weight of the root of Astragalus, 106 parts by weight of the rhizomes Dioscorea, 1060 parts by weight of root Pueraria lobed, 1060 parts by weight of root Trichosanthes, 1060 parts by weight of columns with stigmas of maize, 212 parts by weight of the fruit of Chinese Magnolia vine, and 1 part of weight of Glibenclamide.

4. Medicinal preparation according to claims 1 and 2, or 3, which may be in the form of drops pills, pills, tablets, capsules, dispersible granules, soft capsules or powders.

5. The method of preparation of a medicinal product according to claim 4, containing the following steps: the root of Pueraria lobed, the root of Rehmannii, columns with stigmas of maize, root Trichosanthes, Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea insist with water, then filtered and the filtrate concentrated in moderate scale, to obtain a liquid concentrate, liquid concentrate is placed on cooling; the ethanol is added in liquid concentrate to create a solution containing 60% ethanol, and the solution advocated 24 h, filtered and concentrated to obtain a concentration of unscented ethanol; concentration add two parts of water and cultivat until dissolved; then the resulting solution is placed in a prepared macroporous resin, and the resin elute with water to bleaching eluent, then the resin elute 70%ethanol to discoloration or bleeding C. smooth the project eluent, eluent is collected and concentrated in the extract; a moderate amount of polyethylene Glycol 6000 (Poly ethylene Glycol 6000) and stearic acids are added in a container and heated to 100-110°C until completely dissolved, then add Glibenclamide and extract and uniformly dissolved, then make a drop-pills using liquid paraffin as a cooler, a drop-pills extract and dried on wax.

6. The method of preparation of a medicinal product according to claim 4, containing the following steps: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize insist with water for 5 h, then filtered and the filtrate concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea grind into a fine powder; fine powder added to the liquid concentrate in order to produce granules in single-stage granulator, and Glibenclamide added to the granules, then to be pressed into pills.

7. The method of preparation of a medicinal product according to claim 4, containing the following steps: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize insist with water for 5 h, then filtered and the filtrate concentrated in modest thus, th is would get liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pound in a large powder and large powder mixed well with the liquid concentrate, dried and pounded into a fine powder; fine powder proshlifovat in water, then dried, then add Glibenclamide, pills get using black iron oxide, talc powder and a bonding agent as a covering agent, then polished floor of pills.

8. The method according to claim 7, where the fine powder mix well and make into pills with the help of the device izgotovlyayuschego pills, pills, dried and complement Glibenclamide, pills get using black iron oxide, talc powder and a bonding agent as a covering agent, then Polish the floor and dried.

9. The method according to claim 7, where the fine powder mix well and make into pellets using a single-stage granulator, the granules complement Glibenclamide and pressed into pills.

10. The method of preparation of a medicinal product according to claim 4, containing the following steps: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize insist with water for 5 h, then filtered and the filtrate concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of the Chinese is th lemongrass and rhizome Dioscorea pound in a large powder, and a large powder mixed well with the liquid concentrate, dried and pounded into a fine powder; add Glibenclamide and a moderate amount of dextrin (dextrin) and mix well with a fine powder for the preparation of granules, which are then filled into capsules.

11. The method of preparation of a medicinal product according to claim 4, containing the following steps: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize insist with water for 5 h, then filtered and the filtrate concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pound in a large powder and large powder mixed well with the liquid concentrate, dried and pounded into a fine powder; add Glibenclamide and a moderate amount of dextrin and mix well with a fine powder for the preparation of granules, the granules are then dried, mixed with a moderate amount of stearate (magnesium stearate) and then pressed into tablets.

12. The method of preparation of a medicinal product according to claim 4, containing the following steps: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize insist with water for 5 h, then filtered and the filtrate concentrated in the temperate is assabah thus, to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pound in a large powder and large powder mixed well with the liquid concentrate is then dried and pounded into a fine powder, add Glibenclamide and a moderate amount of dextrin and mix well with a fine powder for the preparation of granules.

13. The method of preparation of a medicinal product according to claim 4, containing the following steps: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize insist with water for 5 h and filtered, then the filtrate concentrated in moderate scale in such a way as to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pound in a large powder and large powder mixed well with the liquid concentrate, dried and pounded into a fine powder; add Glibenclamide and mix well with a fine powder, then add an equal amount of polyethylene Glycol 400 (Poly ethylene Glycol-400) and a small amount of glycerin, mix well and pressed into soft capsules.

14. The method of preparation of a medicinal product according to claim 4, containing the following steps: the root of Rehmannii, the root of Pueraria lobed, the root of Trichosanthes and columns with stigmas of maize insist with water is for 5 h and filtered, then the filtrate was concentrated in modest thus, to obtain a liquid concentrate; Astragalus root, fruit of Chinese Magnolia vine and rhizome Dioscorea pound in a large powder and large powder mixed well with the liquid concentrate is then dried and pounded into a fine powder, add Glibenclamide and mix well with a fine powder for the preparation of powder.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to new coumarin derivatives and their carboxamides, with general formula (I) , where R3 is chosen from a group consisting of H, carboxyl, alkyloxycarbonyl, 5'-(phenyloxadiazol-2')-yl, 5'-(pyridyl-4"-oxadiazol-2')-yl, , CONHR9, where R9 is chosen from a group consisting of fatty acids C2-C8, benzoxamido, isonicotinamido, unsubstituted, or mono-, or polysubstituted phenyl, in which the substitute can be hydroxy, C1-C8-alkoxy, CF3, carboxyl, alkyloxycarbonyl, OCH2CO2H, NO2, halogen, SO3H, SO2NHR11, where R11 is chosen from a group consisting of hydrogen, amidino, 2"-thizolyl, 3"-(511-methylisooxazolyl), 2"-pyrimidinyl, 2"-(4",6"-dimethylpyrimidinyl), 4"-(5",6"-dimethoxypyrimidinyl); R4 is chosen from a group consisting of hydrogen, CONHR10, where R10 is chosen from a group consisting of C2-C8 fatty acids, unsubstituted phenyl; R5 is chosen from a group consisting of H, C1-C4 alkyl; R6 is chosen from a group consisting of H, C1-C12-alkyl, halogen, NO2, CONHR13, where R13 is substituted phenyl; R7 is chosen from a group consisting of H, hydroxyl, C1-C4alkyl or alkoxyl, carboxyalkyleneoxyl, OCH2CONHR14, where R14 is chosen from a group consisting of unsubstituted, mono-, or polysubstituted phenyl, in which the substitute can be hydroxyl, OCH3, CF3, CO2H, CO2C2H5, NO2; R8 is chosen from a group consisting of H, C1-C4-alkyl or alkoxyl, NO2; under the condition that, when R3, R5 and R6 are H, and R7 is OH, R4 and R7 are not groups, chosen from H, C1-C6-alkyl or C1-C6-alkoxy. The invention also relates to pharmaceutical compositions based on formula I compounds and their use as medicinal preparations for protecting kidneys, for curing hypertonia, cardio-cerebrovascular diseases, non-achrestic diabetes, tumours, precancerous diseases and oedema.

EFFECT: enhanced effectiveness of the composition and treatment method.

17 cl, 6 tbl, 51 ex

FIELD: chemistry.

SUBSTANCE: invention relates to aryl or heteroarylpiperazines with general formula II , where R2 is hydrogen or C1-4-alkyl (i) R1 is branched C4-6-alkyl, branched C4-6-alkenyl or branched C4-6-alkynyl, under the condition that R1 is not isobutyl, - C3-5-cycloalkyl, C3-7-cycloalkenyl, C3-6-cycloalkyl-C1-3-alkyl or C3-6-cycloalkenyl-C1-3-alkyl, -R1 and R2 together form a C3-6-alkylene bridge, and A is or or (ii) R1 - is ethyl, n-propyl or isopropyl, - R1 and R2 together form a C3-6-alkylene bridge, and A is or . Described also is a pharmaceutical composition based on formula II compounds, use of formula II compounds and method of treatment.

EFFECT: compounds exhibit high and selective bonding affinity to histamine H3 receptor and can be used for treating diseases and disorders, related to histamine H3 receptor.

49 cl, 149 ex

FIELD: medicine.

SUBSTANCE: invention relates medicine and pharmaceutics area and concerns a pharmaceutical composition possessing antidiabetic, hypolipidemic, hypoglycemic and cholesterol lowering action, containing a chemical combination of the general formula (1) in quality of an active substance, a way of its reception and also ways of treatment and prevention of diabetes, hypolipidemy, hypoglycemia and hypocholesteremia. The composition possesses hypotoxicity and good acceptability.

EFFECT: development of a composition which possesses hypotoxicity and good acceptability.

13 cl, 9 dwg, 6 tbl, 6 ex

FIELD: chemistry; medicine.

SUBSTANCE: invention can be used in production of preparations for treatment of pre-diabetic states, type 2 diabetes and glucose tolerance disturbances. Novel peptides, demonstrating properties of selective receptor VPAC2 agonists, in particular ability to stimulate insulin synthesis and its release from β-cells of pancreas by glucose-depending method, as well as following reduction of glucose level in plasma.

EFFECT: increased efficiency of action and stability in comparison with natural peptides, possibility of their successful application in treatment of diseases.

14 cl, 18 dwg, 1 tbl, 10 ex

FIELD: chemistry; medicine.

SUBSTANCE: in novel triazole derivatives of general formula I or their pharmaceutically acceptable salts R4 is hydrogen; X is selected from group, consisting of single bond, NH- and groups: , values of R1-R3 radicals are given in description, pharmaceutical composition containing them, and application of novel compounds for obtaining medication for treating hyperglycemia, insulin-resistance, type 2 diabetes, fat exchange derangements, obesity, atheroslerosis and metabolic syndrome.

EFFECT: medications possess higher efficiency.

26 cl, 8 ex, 2 tbl

FIELD: chemistry; medicine.

SUBSTANCE: in novel spiropentacyclic compounds of formula (I) R1 and R2 collectively with nitrogen atom, to which they are bound, form 6-member monocyclic saturated heterocyclic ring, which can optionally contain 1 additional O or N; R3 represents hydrogen, halogen or lower alkyl; R4 and R5 each independently represents halogen; and X represents -C(O)- or -SO2-; or their pharmaceutically acceptable salts, intended for application as therapeutically active substances for treatiment and/or prevention of diseases connected with modulation of CB1 receptors and also pharmaceutical composition based on said compounds.

EFFECT: novel compounds possess useful biological properties.

12 cl, 1 tbl, 6 ex

FIELD: chemistry; medicine.

SUBSTANCE: invention relates to 3-phenylpropionic acid derivatives of formula (I) as ligand of peroxisome proliferator-activated gamma-receptor (PPARγ), to their pharmaceutically acceptable salts, as well as to their application, treatment method and based on them pharmaceutical composition. Compounds can be applied for treatment and prevention of diseases mediated by peroxisome proliferator-activated gamma-receptor (PPARγ), for instance type 2 diabetes, insulin-resistance, metabolic syndrome, complications resulting from or connected with diabetes, cardio-vascular dysfunctions, atherosclerosis, obesity, cognition disturbances and lipid metabolism derangements. In general formula (I): W represents COOH or -COO-C1 - C4-alkyl group; Y represents NH; Z represents S or O; X represents O; R1 - R8 each independently represents hydrogen atom or halogen atom; A represents mono-, bi- or tri-cyclic 5-13-member heteroaryl with 1 or 2 heteroatoms selected from N, S or O, aryl, selected from phenyl and naphtyl, or -N(C1-C4-alkyl)-CO-C3-C7-cycloalkyl, where heteroaryl is optionally substituted with 1-3 substituents, independently selected from group, consisting of C1-C4-alkyl, CN, phenyl halogen and phenyl, optionally substituted with 1-3 substituents, independently selected from C1-C4alkoxy, halogen and ethylenedioxy-group; and n represents integer number from 0 to 3 including; and their pharmaceutically acceptable salts.

EFFECT: increased efficiency of composition and treatment method.

20 cl, 14 dwg, 10 ex

FIELD: medicine.

SUBSTANCE: agent for sugar control in patients suffering from diabetes complicated by hepatopathy and bile passages disorders represents the capsules containing mixed dry extract of hill-growing saltwort and microcrystalline cellulose in ratio 1:1 to 1:2.

EFFECT: agent is non-toxic, does not cause by-effects and has no contra-indications to application.

8 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: invention refers to pharmacology. The method for improving amino acid absorption in a vertebrate, including a mammal and a bird, includes introduction to a vertebrate of AKG (alpha-ketoglutaric acid), mono- and dimetallic AKG salts, chitosan-AKG or their mixtures in amount and/or at rate sufficient to maintain the desired effect. The method for decreasing plasma glucose absorption in a vertebrate, including a mammal and a bird, involves introduction to a vertebrate, including a mammal and a bird, of AKG, mono- and dimetallic AKG salts, chitosan-AKG or their mixtures in amount and/or at rate sufficient to maintain the desired effect of glucose absorption. The method of prevention, inhibition or relief of the condition with high-glucose plasma level in a vertebrate, including a mammal and a bird includes introduction to a vertebrate, including a mammal and a bird, of AKG, mono- and dimetallic AKG salts, chitosan-AKG or their mixtures in amount and/or at rate sufficient to maintain the desired effect on the specified condition.

EFFECT: application of AKG, mono- and dimetallic AKG salts, chitosan-AKG or their mixtures in therapeutically effective amount for making the composition used to prevent, relieve and treat the condition with high-glucose plasma level, application of AKG, mono- and dimetallic AKG salts, chitosan-AKG or their mixtures for making the composition used to improve absorption, changed absorption, deteriorated absorption and disordered absorption of amino acids and/or peptides.

19 cl, 3 tbl, 3 ex, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns a pharmaceutical industry, in particular to compositions for treatment of adiposity and resistance to insulin at regulation of levels of glucose in blood. A way of treatment of adiposity and resistance to insulin at regulation of levels of a glucose in the blood, including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures, for resistance treatment to insulin at regulation of levels of a glucose and treatment of adiposity at the patient. Way of treatment of adiposity at the people, suffering diabetes, adiposity and resistance to insulin at regulation of levels of a glucose in blood and accepting a medicinal preparation for treatment of diabetes which includes introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures in a combination to an accepted medicinal preparation for regulation of levels of a glucose and treatment of the people, suffering diabetes. A way of treatment of adiposity and resistance to insulin at regulation of levels of a glucose in blood and the hyperglycaemia treatments, including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures, for treatment of adiposity, resistance to insulin and a hyperglycaemia. Way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and the lipide disturbances, including introduction of therapeutically effective quantity of the composition containing bond, representing an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin and lipide disturbances. Way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and a hypercholesterinemia, including introduction of therapeutically effective quantity of the composition containing bond, representing an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood, a hypercholesteremia. A way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and an atherosclerosis including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and an atherosclerosis. The above described ways of treatment of adiposity, resistance to insulin at regulation of levels of glucose in blood, lipide disturbances, a hypercholesterinemia, an atherosclerosis are effective.

EFFECT: working out of an effective way of treatment of adiposity and resistance to insulin.

16 cl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention concerns a dispersion of crystals or granules of active substance in lipophilic filler where crystals or granules are covered for taste masking. The invention also concerns chewing or quickly dissolved soft gelatinous capsules filled with the specified dispersion, and also a way of manufacture of such forms. Use of considerable quantities of active substance which should be accepted at unitary introduction, and maintenance of satisfactory release of active substance in vivo is possible.

EFFECT: new dosed out forms are stable throughout all period of storage.

15 cl, 17 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: present invention concerns area of medical products, in particular, to the capsule of a medicinal preparation made in the form of an elastic, soluble in a human body, monolithic body with a cavity for placing of a liquid medicinal preparation, having an inflow with a notch on an outer side, with the through aperture executed in it; the capsule is fixed on clothes. Such performance of the capsule excludes leak of a liquid medicinal preparation at an abruption from it, it is convenient for the patient as allows receiving a medicinal preparation in time.

EFFECT: exclusion of leak of a liquid medicinal preparation at an abruption from it, it is convenient for the patient as allows receiving a medicinal preparation in time.

1 dwg, 1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and medicine, namely to oral gindarine medicine characterised as a tranquilizer. Said medicine contains gindarine hydrochloride as an active material and auxiliary components and represents a solid gelatinous capsule. Gindarine is included as a compound of the mass filling capsules as mixed powders of gindarine and auxiliary components or as a granulated material. As the auxiliary components, the medicine contains bulking agent either alone, or combined with a disintegrant or antifriction material or with their mixture. There is also provided method of production of specified oral medicine.

EFFECT: invention provides simplified technological process for making the gindarine medicine, reduction of defective goods, reduced production cost, higher bioavailability of gindarine in comparison with a tableted medical product.

4 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns medical products and concerns capsules for delivery of biologically active agent, containing: a water-soluble, washed away, blasted and-or bulking up cover; and b) the water filling composition including one or more active agents, the water which is in quantity from at least approximately 10% of masses/masses, to less than approximately 70% of masses/weights; and water-soluble derivative cyclodextrin, present at quantity of at least 30% of mass/mass, in recalculation on a total weight of water and derivative cyclodextrin in a filling composition where the quantity derivative cyclodextrin is enough for suppression of dissolution, washing out, destruction and-or a swelling of the cover, caused by water in a filling composition and where the capsule has a period of storage at least one week. Also the way of stabilisation of a capsule is opened.

EFFECT: creation of capsules with steady against dissolution, washing out, destruction and swelling covers.

51 cl, 11 dwg, 11 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition is intended for cancer treatment. As active ingredient composition contains suberoylanilide-hydroxamic acid (SAHA) or its pharmaceutically acceptable salt or hydrate. Invention also relates to method of obtaining crystalline active ingredient SAHA.

EFFECT: definite profile of SAHA particles distribution according to their size, which in its turn results in improved profile of solubility in vitro and optimal SAHA bioavailability.

27 cl, 16 dwg, 22 tbl, 17 ex

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns an oral drug delivery system including biliquid foam containing continuous hydrophilic phase 1 to 20 wt %, pharmaceutically acceptable oil 70 to 98 wt % producing discontinuous phase. A slightly water-soluble drug 0.1 to 20 wt % is dissolved or dispersed in said pharmaceutically acceptable oil. The drug delivery system also contains biliquid foam with included surface-active substance 0.5 to 10 wt % to produce stable biliquid foam with all the amounts specified in percentage of total composition.

EFFECT: drug delivery system ensures high bioavailability of slightly water-soluble oral drugs.

22 cl, 16 ex, 1 tbl

FIELD: medicine; biotechnologies.

SUBSTANCE: method of DNA storage in a redistilled water containing preservative in the form of manganic sulphate in concentration 0.08125 8.125 mM, at temperature -20°C is offered.

EFFECT: prevention of DNA damage by free radicals when storing and can be used in the field of molecular-genetic researches.

1 dwg, 8 ex

FIELD: chemistry.

SUBSTANCE: present invention pertains to crystalline substance for peroral solid medicinal preparation, which is an indoline compound (KMD-3213), which exhibits blocking action to α1-adrinaline receptors, is suitable for use as a therapeutic medium in case of dysuria and is represented by formula (I) . The x-ray diffraction picture of the powder of this compound is characterised by main peaks 5.5°±0.2°, 6.1°±0.2°, 9.8°±0.2°, 11.1°±0.2°, 12.2°±0.2°, 16.4°±0.2°, 19.7°±0.2° and 20.0°±0.2°, as 2θ.

EFFECT: obtaining solid medicinal preparations for treating dysuria, containing this crystalline substance as an active ingredient.

14 cl, 3 dwg, 2 tbl, 9 ex

FIELD: medicine; pharmacology.

SUBSTANCE: pharmaceutical composition includes soft gelatin capsule with filler containing retinoid as active substance, 50 to 80 wt % of natural vegetable oil, 15 to 35 wt % of partially hydrogenised natural vegetable oil, and 3 to 20 wt % of middle-chain triglycerides. Additionally the filler contains 1 to 10 wt % of natural wax. Most preferable implementation version involves soft gelatin capsule includes combination of the described composition and capsule coating containing pig gelatin.

EFFECT: improved composition solubility.

18 cl, 5 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention includes as active substances one or several fibrates and one or several statins or their pharmaceutically comprehensible salt, in carrier chosen from group, consisting of i) admixtures of polyethyleneglycol and poloxamer in the ratio from 2:1 to 3:1 and with the subsequent dispersion on lactose, ii) glyceryl monostearate with the subsequent spraying on lactose or on an admixture of lactose and hydroxypropymethylcellulose; and iii) polyethyleneglycol, with subsequent spraying on Aeroperl. Besides, the invention concerns firm dosed out forms including specified material and way of their obtaining.

EFFECT: possibility to establish suitable biological availability of both active ingredients at peroral insertion.

56 cl, 15 tbl, 15 ex

FIELD: medicine.

SUBSTANCE: invention reveals a composition for reception of the pressed solid dosed out form which represents a free-fluid pressed simethicon admixture, an adsorbent and the unessential active agent where the weight parity of simethicon and an adsorbent makes at least 1:2.22. The invention also opens the solid dosed out forms received from a free-fluid pressed simethicon admixture, an adsorbent and the unessential active agent where the weight parity of simethicon and an adsorbent makes at least 1:2.22.

EFFECT: solid dosed out form contains larger simethicon percentage by weight, having same size as before, or contains the same simethicon percentage by weight in smaller volume.

27 cl, 11 ex

Up!